Please assess the completion status of the following clinical trial:

Trial Title: Pneumococcal Conjugate Vaccine (PCV) in HIV- Infected Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HIV - infected children~   * HIV infected individuals~  * Age between 2 months to 9 years~  * Signed written informed consent~2. HIV - exposed negative children~   * Maternal HIV infection, documented prior to delivery.~  * Age between 2 months to 9 years~  * Signed written informed consent~Exclusion Criteria:~* Active opportunistic infection~* History of hypersensitivity to pneumococcal conjugate vaccine or diphtheria toxoid~* Using oral steroid or immunosuppressive drugs~* Received pneumococcal conjugate vaccine, or pnuemococal polysaccharide vaccine

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: OTHER): Receive valent pneumococcal conjugated vaccine in HIV - infected children
- 2 (Type: OTHER): Receive valent pneumococcal conjugated vaccine in HIV negative children

Based on this trial design, predict the completion outcome and termination type (if applicable).